QOL and Utility in Lung Cancer
863
9. Coons SJ, Rao S, Keininger DL, et al. A comparative review of
generic quality-of-life instruments. Pharmacoeconomics
2000; 17 (1): 13-35
10. Arpinelli F, Visona G, Bruno R, et al. Health-related quality of
life in asymptomatic patients with HIV: evaluation of the SF-
36 health survey in Italian patients. Pharmacoeconomics
2000 Jul; 18 (1): 63-72
11. EuroQoL Group. EuroQol: a new facility for the measurement
of health-related quality of life. HealthPolicy1990; 16:199-208
12. Kurtz ME, Kurtz JC, Stommel M, et al. Loss of physical func-
tioning among geriatric cancer patients: relationships to can-
cer site, treatment, comorbidity and age. Eur J Cancer 1997;
33 (14): 2352-8
13. Mangione CM, Goldman L, Orav EJ, et al. Health-related qual-
ity of life after elective surgery: measurement of longitudinal
changes. J Gen Intern Med 1997; 12 (11): 686-97
14. Wang XS, Cleeland CS, Mendoza TR, et al. The effects of pain
severity on health-related quality of life: a study of Chinese
cancer patients. Cancer 1999; 86 (9): 1848-55
15. Ware Jr JF, Kosnski M, Keller SD. SF-36 physical and mental
health summary scales: a user’s manual. Boston (MA): The
Health Institute, 1994
16. EuroQOL Group Website [online]. Available from URL:
cessed 1999 Apr 15]
17. Apolone G, Mosconi P. The Italian SF-36 health survey: trans-
lation, validation and norming. J Clin Epidemiol 1998; 51:
1025-36
18. Lucioni C, Garancini MP, Massi-Benedetti M, et al. Il costo
sociale del diabete di tipo 2 in Italia: lo studio CODE-2. Phar-
macoeconomics (Italian Research Articles) 2000; 2: 1-21
19. Miller Jr R. Simultaneous statistical inference. New York:
Springer-Verlag, 1981
Acknowledgements
Four educational meetings for the hospital pharmacists in-
volved in the project were funded in part by Eli-Lilly, Spa, Italy.
The list of study participants includes the study coordi-
nators (Trippoli S, Vaiani M, Messori A, Società Italiana di
Farmacia Ospedaliera; Lucioni C, Istituto di Economia San-
itaria, Milano), the 19 participants at the Seminar ‘Master 2
in Farmacoeconomia’(Firenze, 11-12 May 1999, 15-16 June
1999 and 21-22 September 1999; Roma, 15 December 1999)
and the clinicians who were responsible for patient recruit-
ment and quality-of-life interviews. The names and ad-
dresses (all towns/cities in Italy) of seminar participants and
clinicians involved in the project were the following:
Basadonna O, Rampazzo R, Gaion F, Morabito A, Sorarù M
(Camposampiero, Padova); Becagli P, Panella M (Prato);
Bianco MT, Marsili S (Siena); Burlon N, Medici M, Paccag-
nella A(Mestre, Venezia); Cannas A, Massidda B (Cagliari);
Costantini M, Di Turi R, Cipri A, De Marinis F, Portalone L
(Roma); Forresu MC, Staico G, Ortu S (Olbia, Sassari);
Guido MA, Meo AT, Squillacioti A, Anania AM, Bagnato S,
Prantera T(Crotone); Millevoi G, Iop A(Palmanova, Udine);
Pistolesi C, Santo A, Bassetto A, Cetto, GL, Durante E
(Verona); Rinaldi M, Pennucci C, Spinelli I (Carrara);
Scanavacca P, Ballerin L, Indelli M (Ferrara); Sovernigo G,
Bianco A (Conegliano Veneto, Treviso); Spoldi L, Arnoldi
E, Comelli A (Seriate, Bergamo); Lopes Pegna A (Firenze).
References
20. Brooks R. EuroQol: the current state of play. Health Policy
1996; 37: 53-72
1. Montazeri A, Gillis CR, McEwen J. Quality of life in patients
with lung cancer: a review of literature from 1970 to 1995.
Chest 1998; 113 (2): 467-81
21. Aaronson NK, Ahmedzai S, Bergman B, et al. The European
Organization for Research and Treatment of Cancer QLQ-
C30: a quality-of-life instrument for use in international clin-
ical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365-76
22. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity
of the Functional Assessment of Cancer Therapy-Lung
(FACT-L) quality of life instrument. Lung Cancer 1995; 12
(3): 199-220
23. Brazier J, Usherwood T, Harper R, et al. Deriving a preference-
based single index from the UK SF-36 Health Survey. J Clin
Epidemiol 1998; 51 (11): 1115-28
24. Dorman P, Slattery J, Farrell B, et al. Qualitative comparison of
the reliability of health status assessments with the EuroQol
and SF-36 questionnaires after stroke. United Kingdom Col-
laborators in the International Stroke Trial. Stroke 1998; 29
(1): 63-8
2. Hopwood P, Stephens RJ. Depression in patients with lung can-
cer: prevalence and risks factors derived from quality of life
data. J Clin Oncol 2000; 18 (4): 893-7
3. Giaccone G, Splinter TA, Debruyne C, et al. Randomized study
of paclitaxel-cisplatin versus cisplatin-teniposide in patients
with advanced non small cell lung cancer. The European Or-
ganization for Research and Treatment of Cancer Lung Caner
Cooperative Group. J Clin Oncol 1998; 16 (6): 2133-41
4. Helsing M, Bergman B, Thaning L, et al. Quality of life and
survival in patients with advanced non small cell lung cancer
receiving supportive care plus chemotherapy with car-
boplatin and etoposide or supportive care only: a multicentre
randomised phase III trial. Joint Lung Cancer Study Group.
Eur J Cancer 1998; 34 (7): 1036-44
5. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus
best supportive care (BSC) vs BSC in inoperable non-small
cell lung cancer: a randomized trial with quality of life as the
primary outcome. Br J Cancer 2000; 83 (4): 447-53
6. Hollen PJ, Gralla RJ, Kris MG, et al. Normative data and trends
in quality of life from the Lung Cancer Symptom Scale
(LCSS). Support Care Cancer 1999; 7 (3): 140-8
25. Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36
in patients with chronic fatigue syndrome. Qual Life Res
1999; 8 (1-2): 9-16
7. Hollen PJ, Gralla RJ. Comparison of instruments for measuring
quality of life in patients with lung cancer. Semin Oncol 1996;
23 (2 Suppl. 5): 31-40
8. Ware Jr JE, Sherbourne JD. The MOS 36-Item Short-Form
Health Survey (SF-36): I. Conceptual framework and item
selection. Med Care 1992; 30: 473-83
Correspondence and offprints: Dr Andrea Messori,
Laboratorio SIFO di Farmacoeconomia, Drug Information
Center, Azienda Ospedaliera Careggi, viale Morgagni 85,
50134 Florence, Italy.
E-mail: md3439@mclink.it
© Adis International Limited. All rights reserved.
Pharmacoeconomics 2001; 19 (8)